<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.immunome-research.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Immunome Research - Latest Articles</title>
        <link>http://www.immunome-research.com</link>
        <description>The latest research articles published by Immunome Research</description>
        <dc:date>2009-06-17T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/5/1/3" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/5/1/2" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/5/1/1" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/7" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/6" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/5" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/4" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/3" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/2" />
                                <rdf:li rdf:resource="http://www.immunome-research.com/content/4/1/1" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.immunome-research.com/content/5/1/3">
        <title>Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?</title>
        <description>Background:
Previous studies have defined vaccinia virus (VACV)-derived T cell epitopes in VACV-infected human leukocyte antigen-A*0201 (HLA-A2.1) transgenic (Tg) mice and A2.1-positive human Dryvax vaccinees. A total of 14 epitopes were detected in humans and 16 epitopes in A2.1 Tg mice; however, only two epitopes were independently reported in both systems. This limited overlap raised questions about the suitability of using HLA Tg mice as a model system to map human T cell responses to a complex viral pathogen. The present study was designed to investigate this issue in more detail.
Results:
Re-screening the panel of 28 A2.1-restricted epitopes in additional human vaccinees and in A2.1 Tg mice revealed that out of the 28 identified epitopes, 13 were detectable in both systems, corresponding to a 46% concordance rate. Interestingly, the magnitude of responses in Tg mice against epitopes originally identified in humans is lower than for epitopes originally detected in mice. Likewise, responses in humans against epitopes originally detected in Tg mice are of lower magnitude.
Conclusion:
These data suggest that differences in immunodominance patterns might explain the incomplete response overlap, and that with limitations; HLA Tg mice represent a relevant and suitable model system to study immune responses against complex pathogens.</description>
        <link>http://www.immunome-research.com/content/5/1/3</link>
                <dc:creator>Maya Kotturi</dc:creator>
                <dc:creator>Erika Assarsson</dc:creator>
                <dc:creator>Bjoern Peters</dc:creator>
                <dc:creator>Howard Grey</dc:creator>
                <dc:creator>Carla Oseroff</dc:creator>
                <dc:creator>Valerie Pasquetto</dc:creator>
                <dc:creator>Alessandro Sette</dc:creator>
                <dc:source>Immunome Research 2009, 5:3</dc:source>
        <dc:date>2009-06-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-5-3</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-06-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/5/1/2">
        <title>Functional recombinant MHC class II molecules and high-throughput peptide-binding assays</title>
        <description>Background:
Molecules of the class II major histocompability complex (MHC-II) specifically bind and present exogenously derived peptide epitopes to CD4+ T helper cells. The extreme polymorphism of the MHC-II hampers the complete analysis of peptide binding. It is also a significant hurdle in the generation of MHC-II molecules as reagents to study and manipulate specific T helper cell responses. Methods to generate functional MHC-II molecules recombinantly, and measure their interaction with peptides, would be highly desirable; however, no consensus methodology has yet emerged.
Results:
We generated &#945; and &#946; MHC-II chain constructs, where the membrane-spanning regions were replaced by dimerization motifs, and the C-terminal of the &#946; chains was fused to a biotinylation signal peptide (BSP) allowing for in vivo biotinylation. These chains were produced separately as inclusion bodies in E. coli , extracted into urea, and purified under denaturing and non-reducing conditions using conventional column chromatography. Subsequently, diluting the two chains into a folding reaction with appropriate peptide resulted in efficient peptide-MHC-II complex formation. Several different formats of peptide-binding assay were developed including a homogeneous, non-radioactive, high-throughput (HTS) binding assay. Binding isotherms were generated allowing the affinities of interaction to be determined. The affinities of the best binders were found to be in the low nanomolar range. Recombinant MHC-II molecules and accompanying HTS peptide-binding assay were successfully developed for nine different MHC-II molecules including the DPA1*0103/DPB1*0401 (DP401) and DQA1*0501/DQB1*0201, where both &#945; and &#946; chains are polymorphic, illustrating the advantages of producing the two chains separately.
Conclusion:
We have successfully developed versatile MHC-II resources, which may assist in the generation of MHC class II -wide reagents, data, and tools.</description>
        <link>http://www.immunome-research.com/content/5/1/2</link>
                <dc:creator>Sune Justesen</dc:creator>
                <dc:creator>Mikkel Harndahl</dc:creator>
                <dc:creator>Kasper Lamberth</dc:creator>
                <dc:creator>Lise-Lotte Nielsen</dc:creator>
                <dc:creator>Soren Buus:</dc:creator>
                <dc:source>Immunome Research 2009, 5:2</dc:source>
        <dc:date>2009-05-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-5-2</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-05-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/5/1/1">
        <title>Genetic correlates of autoreactivity and autoreactive potential in human Ig heavy chains</title>
        <description>Background:
Immature bone marrow B cells are known to have longer CDR3 than mature peripheral B cells, and this genetic characteristic has been shown to correlate with autoreactivity in these early cells. B-cell Central tolerance eliminates these cells, but it is known that autoreactive B cells nevertheless appear commonly in healthy human blood. We examined over 7,300 Ig genes from Genbank, including those annotated by their discoverers as associated with autoreactivity, to determine the genetic correlates of autoreactivity in mature B cells.
Results:
We find differential biases in gene segment usage and higher mutation frequency in autoreactivity-associated Ig genes, but the CDR3 lengths do not differ between autoreactive and non-autoreactive Ig genes. The most striking genetic signature of autoreactivity is an increase in the proportion of N-nucleotides relative to germline-encoded nucleotides in CDR3 from autoreactive genes.
Conclusion:
We hypothesize that peripheral autoreactivity results primarily from somatic mutation, and that the genetic correlates of autoreactivity in mature B-cells are not the same as those for autoreactivity in immature B cells. What is seen in mature autoreactive B cells are the correlates of autoreactive potential, not of autoreactivity per se. The autoreactive potential is higher for V(D)J rearrangements encoded to a large extent by N-nucleotides rather than by the gene segments that, we posit, have been selected in germline evolution for their suppression of autoreactive potential.</description>
        <link>http://www.immunome-research.com/content/5/1/1</link>
                <dc:creator>Joseph Volpe</dc:creator>
                <dc:creator>Thomas Kepler</dc:creator>
                <dc:source>Immunome Research 2009, 5:1</dc:source>
        <dc:date>2009-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-5-1</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2009-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/7">
        <title>Data mining of cancer vaccine trials: a bird&apos;s-eye view</title>
        <description>Background:
A wealth of information on clinical trials has been provided by publicly accessible online registries. Information technology and data exchange standards enable rapid extraction, summarization, and visualization of information and derived knowledge from these data sets. Clinical trials data was extracted in the XML format from the National Library of Medicine ClinicalTrials.gov site. This data includes categories such as &apos;Summary of Purpose&apos;, &apos;Trial Sponsor&apos;, &apos;Phase of the Trial&apos;, &apos;Recruiting Status&apos;, and &apos;Location&apos;. We focused on 645 clinical trials related to cancer vaccines. Additional facts on cancer types, including incidence and survival rates, were retrieved from the National Cancer Institute Surveillance data.
Results:
This application enables rapid extraction of information about institutions, diseases, clinical approaches, clinical trials dates, predominant cancer types in the trials, clinical opportunities and pharmaceutical market coverage. Presentation of results is facilitated by visualization tools that summarize the landscape of ongoing and completed cancer vaccine trials. Our summaries show the number of clinical vaccine trials per cancer type, over time, by phase, by lead sponsors, as well as trial activity relative to cancer type and survival data. We also have identified cancers that are neglected in the cancer vaccine field: bladder, liver, pancreatic, stomach, esophageal, and all of the low-incidence cancers.
Conclusion:
We have developed a data mining approach that enables rapid extraction of complex data from the major clinical trial repository. Summarization and visualization of these data represents a cost-effective means of making informed decisions about future cancer vaccine clinical trials.</description>
        <link>http://www.immunome-research.com/content/4/1/7</link>
                <dc:creator>Xiaohong Cao</dc:creator>
                <dc:creator>Karen Maloney</dc:creator>
                <dc:creator>Vladimir Brusic</dc:creator>
                <dc:source>Immunome Research 2008, 4:7</dc:source>
        <dc:date>2008-12-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-7</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2008-12-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/6">
        <title>Peptide length significantly influences in vitro affinity for MHC class II molecules</title>
        <description>Background:
Class II Major Histocompatibility Complex (MHC) molecules have an open-ended binding groove which can accommodate peptides of varying lengths. Several studies have demonstrated that peptide flanking residues (PFRs) which lie outside the core binding groove can influence peptide binding and T cell recognition. By using data from the AntiJen database we were able to characterise systematically the influence of PFRs on peptide affinity for MHC class II molecules.
Results:
By analysing 1279 peptide elongation events covering 19 distinct HLA alleles it was observed that, in general, peptide elongation resulted in increased MHC class II molecule affinity. It was also possible to determine an optimal peptide length for MHC class II affinity of approximately 18&#8211;20 amino acids; elongation of peptides beyond this length resulted in a null or negative effect on affinity.
Conclusion:
The observed relationship between peptide length and MHC class II affinity has significant implications for the design of vaccines and the study of the epitopic basis of immunological disease.</description>
        <link>http://www.immunome-research.com/content/4/1/6</link>
                <dc:creator>Cathal O'Brien</dc:creator>
                <dc:creator>Darren Flower</dc:creator>
                <dc:creator>Conleth Feighery</dc:creator>
                <dc:source>Immunome Research 2008, 4:6</dc:source>
        <dc:date>2008-11-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-6</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2008-11-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/5">
        <title>Expression Analysis of G Protein-Coupled Receptors in Mouse Macrophages</title>
        <description>Background:
Monocytes and macrophages express an extensive repertoire of G Protein-Coupled Receptors (GPCRs) that regulate inflammation and immunity. In this study we performed a systematic micro-array analysis of GPCR expression in primary mouse macrophages to identify family members that are either enriched in macrophages compared to a panel of other cell types, or are regulated by an inflammatory stimulus, the bacterial product lipopolysaccharide (LPS).
Results:
Several members of the P2RY family had striking expression patterns in macrophages; P2ry6 mRNA was essentially expressed in a macrophage-specific fashion, whilst P2ry1 and P2ry5 mRNA levels were strongly down-regulated by LPS. Expression of several other GPCRs was either restricted to macrophages (e.g. Gpr84) or to both macrophages and neural tissues (e.g. P2ry12, Gpr85). The GPCR repertoire expressed by bone marrow-derived macrophages and thioglycollate-elicited peritoneal macrophages had some commonality, but there were also several GPCRs preferentially expressed by either cell population.
Conclusion:
The constitutive or regulated expression in macrophages of several GPCRs identified in this study has not previously been described. Future studies on such GPCRs and their agonists are likely to provide important insights into macrophage biology, as well as novel inflammatory pathways that could be future targets for drug discovery.</description>
        <link>http://www.immunome-research.com/content/4/1/5</link>
                <dc:creator>Jane Lattin</dc:creator>
                <dc:creator>Kate Schroder</dc:creator>
                <dc:creator>Andrew Su</dc:creator>
                <dc:creator>John Walker</dc:creator>
                <dc:creator>Jie Zhang</dc:creator>
                <dc:creator>Tim Wiltshire</dc:creator>
                <dc:creator>Kaoru Saijo</dc:creator>
                <dc:creator>Christopher Glass</dc:creator>
                <dc:creator>David Hume</dc:creator>
                <dc:creator>Stuart Kellie</dc:creator>
                <dc:creator>Matthew Sweet</dc:creator>
                <dc:source>Immunome Research 2008, 4:5</dc:source>
        <dc:date>2008-04-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-5</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2008-04-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/4">
        <title>Efficiency of the immunome protein interaction network increases during evolution</title>
        <description>Background:
Details of the mechanisms and selection pressures that shape the emergence and development of complex biological systems, such as the human immune system, are poorly understood. A recent definition of a reference set of proteins essential for the human immunome, combined with information about protein interaction networks for these proteins, facilitates evolutionary study of this biological machinery.
Results:
Here, we present a detailed study of the development of the immunome protein interaction network during eight evolutionary steps from Bilateria ancestors to human. New nodes show preferential attachment to high degree proteins. The efficiency of the immunome protein interaction network increases during the evolutionary steps, whereas the vulnerability of the network decreases.
Conclusion:
Our results shed light on selective forces acting on the emergence of biological networks. It is likely that the high efficiency and low vulnerability are intrinsic properties of many biological networks, which arise from the effects of evolutionary processes yet to be uncovered.</description>
        <link>http://www.immunome-research.com/content/4/1/4</link>
                <dc:creator>Csaba Ortutay</dc:creator>
                <dc:creator>Mauno Vihinen</dc:creator>
                <dc:source>Immunome Research 2008, 4:4</dc:source>
        <dc:date>2008-04-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-4</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2008-04-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/3">
        <title>Large-scale analysis of human heavy chain V(D)J recombination patterns</title>
        <description>Background:
The processes involved in the somatic assembly of antigen receptor genes are unique to the immune system and are driven largely by random events. Subtle biases, however, may exist and provide clues to the molecular mechanisms involved in their assembly and selection. Large-scale efforts to provide baseline data about the genetic characteristics of immunoglobulin (Ig) genes and the mechanisms involved in their assembly have recently become possible due to the rapid growth of genetic databases.
Results:
We gathered and analyzed nearly 6,500 productive human Ig heavy chain genes and compared them with 325 non-productive Ig genes that were originally rearranged out of frame and therefore incapable of being biased by selection. We found evidence for differences in n-nucleotide tract length distributions which have interesting interpretations for the mechanisms involved in n-nucleotide polymerization. Additionally, we found striking statistical evidence for pairing preferences among D and J segments. We present a statistical model to support our hypothesis that these pairing biases are due to multiple sequential D-to-J rearrangements.
Conclusion:
We present here the most precise estimates of gene segment usage frequencies currently available along with analyses regarding n-nucleotide distributions and D-J segment pair preferences. Additionally, we provide the first statistical evidence that sequential D-J recombinations occur at the human heavy chain locus during B-cell ontogeny with an approximate frequency of 20%.</description>
        <link>http://www.immunome-research.com/content/4/1/3</link>
                <dc:creator>Joseph Volpe</dc:creator>
                <dc:creator>Thomas Kepler</dc:creator>
                <dc:source>Immunome Research 2008, 4:3</dc:source>
        <dc:date>2008-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-3</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2008-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/2">
        <title>Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries</title>
        <description>Background:
It has been previously shown that combinatorial peptide libraries are a useful tool to characterize the binding specificity of class I MHC molecules. Compared to other methodologies, such as pool sequencing or measuring the affinities of individual peptides, utilizing positional scanning combinatorial libraries provides a baseline characterization of MHC molecular specificity that is cost effective, quantitative and unbiased.
Results:
Here, we present a large-scale application of this technology to 19 different human and mouse class I alleles. These include very well characterized alleles (e.g. HLA A*0201), alleles with little previous data available (e.g. HLA A*3201), and alleles with conflicting previous reports on specificity (e.g. HLA A*3001). For all alleles, the positional scanning combinatorial libraries were able to elucidate distinct binding patterns defined with a uniform approach, which we make available here. We introduce a heuristic method to translate this data into classical definitions of main and secondary anchor positions and their preferred residues. Finally, we validate that these matrices can be used to identify candidate MHC binding peptides and T cell epitopes in the vaccinia virus and influenza virus systems, respectively.
Conclusion:
These data confirm, on a large scale, including 15 human and 4 mouse class I alleles, the efficacy of the positional scanning combinatorial library approach for describing MHC class I binding specificity and identifying high affinity binding peptides. These libraries were shown to be useful for identifying specific primary and secondary anchor positions, and thereby simpler motifs, analogous to those described by other approaches. The present study also provides matrices useful for predicting high affinity binders for several alleles for which detailed quantitative descriptions of binding specificity were previously unavailable, including A*3001, A*3201, B*0801, B*1501 and B*1503.</description>
        <link>http://www.immunome-research.com/content/4/1/2</link>
                <dc:creator>John Sidney</dc:creator>
                <dc:creator>Erika Assarsson</dc:creator>
                <dc:creator>Carrie Moore</dc:creator>
                <dc:creator>Sandy Ngo</dc:creator>
                <dc:creator>Clemencia Pinilla</dc:creator>
                <dc:creator>Alessandro Sette</dc:creator>
                <dc:creator>Bjoern Peters</dc:creator>
                <dc:source>Immunome Research 2008, 4:2</dc:source>
        <dc:date>2008-01-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-2</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2008-01-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunome-research.com/content/4/1/1">
        <title>Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins</title>
        <description>Background:
The application of peptide based diagnostics and therapeutics mimicking part of protein antigen is experiencing renewed interest. So far selection and design rationale for such peptides is usually driven by T-cell epitope prediction, available experimental and modelled 3D structure, B-cell epitope predictions such as hydrophilicity plots or experience. If no structure is available the rational selection of peptides for the production of functionally altering or neutralizing antibodies is practically impossible. Specifically if many alternative antigens are available the reduction of required synthesized peptides until one successful candidate is found is of central technical interest. We have investigated the integration of B-cell epitope prediction with the variability of antigen and the conservation of patterns for post-translational modification (PTM) prediction to improve over state of the art in the field. In particular the application of machine-learning methods shows promising results.
Results:
We find that protein regions leading to the production of functionally altering antibodies are often characterized by a distinct increase in the cumulative sum of three presented parameters. Furthermore the concept to maximize antigenicity, minimize variability and minimize the likelihood of post-translational modification for the identification of relevant sites leads to biologically interesting observations. Primarily, for about 50% of antigen the approach works well with individual area under the ROC curve (AROC) values of at least 0.65. On the other hand a significant portion reveals equivalently low AROC values of &lt; = 0.35 indicating an overall non-Gaussian distribution. While about a third of 57 antigens are seemingly intangible by our approach our results suggest the existence of at least two distinct classes of bioinformatically detectable epitopes which should be predicted separately. As a side effect of our study we present a hand curated dataset for the validation of protectivity classification. Based on this dataset machine-learning methods further improve predictive power to a class separation in an equilibrated dataset of up to 83%.
Conclusion:
We present a computational method to automatically select and rank peptides for the stimulation of potentially protective or otherwise functionally altering antibodies. It can be shown that integration of variability, post-translational modification pattern conservation and B-cell antigenicity improve rational selection over random guessing. Probably more important, we find that for about 50% of antigen the approach works substantially better than for the overall dataset of 57 proteins. Essentially as a side effect our method optimizes for presumably best applicable peptides as they tend to be likely unmodified and as invariable as possible which is answering needs in diagnosis and treatment of pathogen infection. In addition we show the potential for further improvement by the application of machine-learning methods, in particular Random Forests.</description>
        <link>http://www.immunome-research.com/content/4/1/1</link>
                <dc:creator>Johannes Sollner</dc:creator>
                <dc:creator>Rainer Grohmann</dc:creator>
                <dc:creator>Ronald Rapberger</dc:creator>
                <dc:creator>Paul Perco</dc:creator>
                <dc:creator>Arno Lukas</dc:creator>
                <dc:creator>Bernd Mayer</dc:creator>
                <dc:source>Immunome Research 2008, 4:1</dc:source>
        <dc:date>2008-01-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-7580-4-1</dc:identifier>
        <prism:publicationName>Immunome Research</prism:publicationName>
        <prism:issn>1745-7580</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2008-01-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
